Cells, Tissues And Organs Surveillance System (CTOSS), 2023
Download the alternative format
(PDF format, 1.98 MB, 1 page)
Organization: Public Health Agency of Canada
Published: 2025-02-06
CTOSS monitors adverse events related to transplantation of cells, tissues, and organs in Canada.
2011 The system started in 2011. Currently, it only covers tissue transplants. The link contains a detailed methodology of surveillance.
30% of the tissues transplanted in Canada are monitored through four participating provinces in CTOSS.
82,129 tissues were transplanted during 2011-2023.
9,409 tissues were transplanted in 2023.
52 transplantation adverse events (TAEsFootnote *) were reported during 2011-2023.
7 TAEs were reported related to ocular tissues during 2023. All TAEs were graft rejections.
The incidence rate was 4.33 TAEs/1,000 grafts.
Number Of Tissues Transplanted By Sites, CTOSS 2023Footnote *
Footnote *For Alberta, AB Health Services covers Northern Alberta regions.
Tissues Transplanted, 2022
- 6,347 Quebec
- 895 Nova Scotia
- 1,802 Alberta
- 365 New Brunswick
Total Tissues Transplanted By Tissue Types, CTOSS 2023
- 4065 Bone
- 1667 Skin
- 1281 Ocular Tissue
- 1016 Tendon
- 587 Heart Valve
- 13 Fascia
- 334 Amniotic Membrance
- 446 Other Allografts
- 9409 Total
Tissues Involving Adverse Events (N=52), CTOSS 2011-2023
- Ocular (37, 71%)
- Bone (11, 21%)
- Tendon (3, 6%)
- Heart Valve (1, 2%)
With reduced number of tissues transplanted in 2023, the incidence rates of TAEs in four sites slightly increased.
Footnotes
- Footnote *
-
TAE: Any unintended or untoward medical occurrence that may be consequent or related to cells, tissues, or organs that are transplanted. An adverse event may be considered to be an incident or reaction.